TL;DR
- •Vyvanse (lisdexamfetamine) is a prodrug — it's converted to dextroamphetamine in the body. So the pharmacologic profile resembles Adderall, but with slower onset and smoother kinetics that reduce abuse potential.
- •Discontinuation produces the same stimulant-class withdrawal pattern as Adderall: crash, fatigue, anhedonia rebound, brain fog, increased appetite, depressed mood. Not classical antidepressant-style withdrawal.
- •Because Vyvanse is a prodrug with smoother plasma kinetics, the crash on discontinuation is sometimes reported as slightly less abrupt than Adderall — though the magnitude is similar for equivalent doses.
- •Vyvanse is FDA-approved for ADHD AND binge-eating disorder. For binge-eating-disorder patients, discontinuation may be motivated by different concerns than for ADHD patients — and the relapse risk pattern differs.
- •Vyvanse is Schedule II — same controlled-substance status as Adderall, with the same prescribing constraints (monthly refills, no automatic refills, prescriber visits required).
- •For patients with comorbid depression using Vyvanse partly for mood elevation, ketamine offers a different mechanism that doesn't produce a crash on discontinuation.
Why people decide to taper
- •Cardiovascular concerns (blood pressure, heart rate, palpitations)
- •Tolerance — the original dose no longer produces the expected effect
- •Sleep disruption from afternoon-effect lingering
- •Original ADHD or binge-eating-disorder symptoms manageable through other means
- •Pregnancy planning
- •Concern about long-term dopaminergic effects
- •Cost — Vyvanse generic availability is improving but remains expensive in some markets
What withdrawal looks like
Vyvanse withdrawal follows the same pattern as Adderall withdrawal: crash with fatigue, hypersomnia, depressed mood, brain fog, anhedonia rebound, increased appetite. Because Vyvanse's prodrug kinetics produce smoother plasma levels, the crash onset can be marginally smoother than Adderall — but the magnitude is similar for equivalent dextroamphetamine exposure. Onset is within 12-24 hours of the last dose; acute crash 3-7 days; lingering low mood and reduced motivation can persist for weeks to months in chronic high-dose users. NO physical withdrawal syndrome — no tremors, no seizures.
Typical taper timeline
Vyvanse tapers are typically shorter than antidepressant tapers — often 1-4 weeks for short-term users and 4-8 weeks for long-term high-dose users. The available dose strengths (10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg) support reasonable step reductions. Chronic high-dose users (60-70mg/day) often benefit from a slower 6-12 week taper to reduce crash intensity.
Taper approaches
Options to bring to your prescriber. The dose-by-dose plan belongs to your prescriber, not this page.
Linear dose reduction
Reduce by 10-20mg increments every 1-2 weeks. The granular dose strengths (10mg through 70mg in 10mg increments) support reasonable taper steps without needing compounded formulations.
Vyvanse capsule sprinkle (off-label fine titration)
Vyvanse capsules can be opened and the contents dissolved in water or applied to soft food — this allows partial-dose taper at increments finer than the 10mg tablet steps. Discuss with your prescriber before doing this; it's sometimes used for sensitive patients during the final taper stages.
Drug holidays as discovery period
Some patients use weekend-off or vacation-off periods to characterize their functioning without the medication. This reveals whether the original ADHD or binge-eating-disorder symptoms still need stimulant treatment.
Switch to non-stimulant before stopping
For patients still needing ADHD treatment, transitioning to atomoxetine, guanfacine, or viloxazine before discontinuing Vyvanse provides ongoing symptom control. For binge-eating-disorder, alternative treatments include cognitive-behavioral therapy and other medications (topiramate, off-label).
Address comorbid depression with ketamine
For patients using Vyvanse partly for mood elevation, ketamine's rapid antidepressant effect provides a different mechanism for the mood component. This separates the ADHD/BED-treatment question from the depression-treatment question.
What’s specific to Vyvanse (Lisdexamfetamine)
Vyvanse is lisdexamfetamine dimesylate — a prodrug consisting of dextroamphetamine bonded to L-lysine. The molecule is pharmacologically inactive until enzymatic cleavage in red blood cells releases free dextroamphetamine. This activation mechanism produces several distinguishing features: slower onset of action (1-2 hours vs Adderall IR's 30-60 min), smoother plasma curve, less peak-to-trough variability, harder to abuse via routes other than oral. Half-life of the active dextroamphetamine after Vyvanse dosing is ~12 hours functional duration. Vyvanse is Schedule II controlled substance with the same prescribing restrictions as Adderall. The dose strengths (10/20/30/40/50/60/70mg capsules) provide good granularity for tapering. Vyvanse's prodrug kinetics make it preferred over Adderall in patients with substance-use history or concerns about misuse. For tapering, the smoother kinetics translate to slightly less dramatic crashes between dose reductions, but the underlying stimulant-class discontinuation pattern is the same.
Where ketamine fits
Vyvanse patients with comorbid depression face the same situation as Adderall patients — the stimulant may be partly treating mood and not just ADHD or binge-eating disorder. Ketamine's NMDA/glutamate mechanism offers a different mood pathway that doesn't produce a crash on discontinuation. The transition pattern: start ketamine while still on Vyvanse, confirm mood response, then taper Vyvanse with mood support maintained through ketamine's ongoing effect. For pure ADHD without comorbid depression, ketamine isn't the right tool — non-stimulant ADHD treatments (atomoxetine, guanfacine) are the alternative. But for the comorbid pattern, ketamine can change the prescribing calculus significantly by separating the mood treatment from the stimulant treatment.
Check eligibility for ketamine therapy5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Is Vyvanse easier or harder to come off than Adderall?
Slightly easier in practice for many patients, because the prodrug kinetics produce smoother plasma levels and less abrupt peak-to-trough variation. The crash on discontinuation is comparable in magnitude to Adderall for equivalent dextroamphetamine exposure, but sometimes reported as smoother in onset. Neither is dramatically harder than the other — both are stimulant-class with similar withdrawal patterns.
How long does the Vyvanse crash last?
Acute crash: 3-7 days. Lingering low mood and reduced motivation: weeks to months for chronic high-dose users. Short-term users typically recover within 2 weeks. Pattern is essentially identical to Adderall withdrawal.
Can I open Vyvanse capsules to reduce the dose?
Yes — Vyvanse capsules can be opened and the contents dissolved in water or applied to soft food. Some patients and prescribers use this for finer dose adjustments than the 10mg tablet increments allow. Discuss with your prescriber before doing this; it's off-label but recognized.
I take Vyvanse for binge-eating disorder, not ADHD. Will the BED come back during taper?
Possibly. Vyvanse is FDA-approved for binge-eating disorder, and discontinuation can be followed by return of binge-eating symptoms. The taper should include consideration of alternative BED treatments — cognitive-behavioral therapy is first-line, topiramate (off-label) and other medications are options. Discuss the transition plan with your prescriber.
Will ketamine help me come off Vyvanse?
For patients using Vyvanse partly for mood elevation alongside the primary indication, yes — ketamine provides a different mood mechanism that doesn't produce a crash on discontinuation. For pure ADHD or pure BED without comorbid depression, ketamine isn't the right tool; non-stimulant alternatives are more appropriate.
Never taper without prescriber coordination
Withdrawal symptoms can mimic depression or anxiety relapse, and untreated relapse can be more dangerous than withdrawal. Stopping benzodiazepines abruptly can produce seizures. Bring this page to your prescriber as a conversation starter — they translate options into your specific plan.
References
- SilvaCarvalho M et al. 2025, Basic & Clinical Pharmacology & Toxicology. Comprehensive evaluation of lisdexamfetamine pharmacology, therapeutic use, toxicity, and discontinuation profile — including prodrug kinetics and the resulting smoother plasma curve. (Author per PubMed: Silva-Carvalho M) PMID 41001763
- Ebina T et al. 2026, PCN Reports. ADHD medication discontinuation patterns and withdrawal experiences — characterizes the crash phenomenon shared across stimulant agents. PMID 42021984
- Poorvii R et al. 2026, Frontiers in Psychology. Systematic review of cognitive effects of amphetamine withdrawal — relevant translational evidence for cognitive/motivational crash following stimulant discontinuation including lisdexamfetamine. PMID 41969881